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Abstract
Background: One of the challenges in the interpretation of studies showing associations between environmental
and genotypic data with disease outcomes such as neovascular age-related macular degeneration (AMD) is
understanding the phenotypic heterogeneity within a patient population with regard to any risk factor associated
with the condition. This is critical when considering the potential therapeutic response of patients to any drug
developed to treat the condition. In the present study, we identify patient subtypes or clusters which could
represent several different targets for treatment development, based on genetic pathways in AMD and
cardiovascular pathology.
Methods: We identified a sample of patients with neovascular AMD, that in previous studies had been shown to
be at elevated risk for the disease through environmental factors such as cigarette smoking and genetic variants
including the complement factor H gene (CFH) on chromosome 1q25 and variants in the ARMS2/HtrA serine
peptidase 1 (HTRA1) gene(s) on chromosome 10q26. We conducted a multivariate segmentation analysis of 253 of
these patients utilizing available epidemiologic and genetic data.
Results: In a multivariate model, cigarette smoking failed to differentiate subtypes of patients. However, four
meaningfully distinct clusters of patients were identified that were most strongly differentiated by their
cardiovascular health status (histories of hypercholesterolemia and hypertension), and the alleles of ARMS2/HTRA1
rs1049331.
Conclusions: These results have significant personalized medicine implications for drug developers attempting to
determine the effective size of the treatable neovascular AMD population. Patient subtypes or clusters may
represent different targets for therapeutic development based on genetic pathways in AMD and cardiovascular
pathology, and treatments developed that may elevate CV risk, may be ill advised for certain of the clusters
identified.
Background
The current medical literature is increasing weekly with
studies identifying DNA variants and their possible inter-
action with environmental factors that may have impact
on risk of disease. The growth of such studies has been
spurred by the promise of understanding the genetic and
environmental basis of complex diseases, and the
possibility of identifying therapeutically responsive targets
for drug development. Enormous numbers of DNA var-
iants have been associated with diseases and traits and this
number will only grow as it becomes economically feasible
to sequence an individual patient’s entire genome[1].
One key data interpretation challenge lies in how best
to assess the phenotypic heterogeneity and risk factor
heterogeneity within the affected patient population.
Even in situations where the association between a risk
factor and disease is highly significant, there are indivi-
duals with the disease who do not manifest all risk factors
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The presence of a risk factor is not a sufficient determi-
nant of disease. This point is a critical consideration in
drug development, as the effective size of the patient
population that may be treated with a drug designed to
target a particular genetic risk factor may in fact be much
smaller than the total patient population. This has impli-
cations for the design of clinical trials that may incorpo-
rate genetic data, and ultimately for decisions on the
feasibility of producing a medication.
Age-related macular degeneration (AMD) is an exam-
ple of a complex disease that has been shown to have
clear genetic and environmental antecedents. The lead-
ing cause of visual loss in the aging population, neovas-
cular AMD is characterized by the growth of abnormal
new blood vessels underlying the retina which can cause
severe and rapid vision loss due to hemorrhage and exu-
dation (for review please see Miller, 2008)[3].
The general population harbors both modifiable and
non-modifiable characteristics associated with AMD,
however, the current study examines the afflicted sub-
sample of population rather than at the entire popula-
tion. Prior epidemiologic characteristics shown to be
associated with the risk of AMD include age, gender,
elevated body mass index (BMI), hyperlipidemia, hyper-
tension, and cigarette smoking[4-12]. These factors are
all well-documented to be associated with the risk of
cardiovascular disease, and events such as myocardial
infarction and stroke. In terms of cardiovascular risk
factors, several studies have found that cigarette smok-
ing (perhaps through oxidative stress and injury) ele-
vates the risk of AMD[13,14]. Another risk factor
associated with cardiovascular disease is heavy alcohol
consumption, which has also been shown to be asso-
ciated with late-stage AMD, including neovascular AMD
in one study, [7] but, other studies were unable to repli-
cate this association[15-17]. Similarly, elevated BMI has
been shown to be associated with AMD progression[18]
and also elevated risk of AMD[19,20].
Cholesterol and lipid metabolism have been implicated
in the pathogenesis of AMD,[21-32] and there is evi-
dence both for and against the hypothesis that choles-
terol lowering statin therapy may have a protective
effect on the development of AMD[33-36]. In terms of
hypertension, there is conflicting evidence supporting an
association with neovascular AMD[6,19,37,38].
Several genes have been associated with all subtypes
of AMD, including the advanced stages, with the most
strongly associated variants seen within the comple-
ment factor H (CFH) gene on chromosome 1q25. The
CFH gene is known to play a role in the immune/
inflammatory system[39-43]. Additionally, other
strongly associated variants with large influence on
AMD risk, particularly the neovascular subtype, are
found in the ARMS2/ HTRA1 genes on chromosome
10q26[44-49].
Nevertheless, the ability to predict AMD risk would be
greatly enhanced if both the effects of genetic and envir-
onmental risk factors were considered collectively,[5]
although the degree to which these factors interact in
the risk of AMD or its progression is unclear. For exam-
ple, although cigarette smoking has been shown to ele-
vate the risk of AMD and its progression, significant
interactions between smoking and CFH variants in pre-
dicting AMD risk have not been shown[50,51]. While
there is one report of variation within ARMS2 and inter-
action with smoking,[52] others have not demonstrated
this finding[46,49]. In terms of cardiovascular risk fac-
tors, when smoking was included in a multivariate
model, alcohol consumption, hypertension, and BMI
were no longer associated with neovascular AMD. Only
history of cigarette smoking remained significantly asso-
ciated with neovascular AMD, with each pack-year
being associated with a 2% increase in the risk of dis-
ease[17]. Therefore it is important that presymptomatic
diagnostic tests (and presumably any therapeutic agents
in development) should be designed to take into
account the assessment of all informative genetic var-
iants along with documented disease associated environ-
mental factors[2,51].
Recognizing that any patient population with the same
disease phenotype will be heterogeneous to some degree
for any single risk factor or collection of factors, it is cri-
tical that a multivariate or multifactor approach is used
to consider risk. Another important consideration in
interpreting measures of association is that although the
association may be statistically significant, not all cases
with the disease will have the risk factor. For example,
our group has shown that having two copies of the risk
allele (TT) at ARMS2/HTRA1 rs1049331 significantly
increases risk of developing neovascular AMD when
compared to individuals who are homozygous for the
common allele (CC), with many times greater magni-
tude of effect than important non-genetic factors such
as smoking[50]. However, it should be kept in mind that
only 33% of the neovascular AMD patients evaluated
actually carry the TT genotype, relative to 16% of their
matched sibling controls.
Consequently, it is reasonable to hypothesize that
appropriately designed studies may be able to identify
meaningfully distinct subtypes or clusters of patients
within the neovascular AMD population on the basis of
genetic or environmental characteristics predictive of
the risk of disease. If, for example, a pharmaceutical
company was developing a drug specifically targeting
neovascular AMD that focused on specific genetic and
cardiovascular risk characteristics, the actual patient
population that might be responsive or benefit from
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comprising only those patients with that particular risk
profile. There may well be overlapping pathophysiologi-
cal antecedents between risk of cardiovascular disease
and neovascular AMD[4,10-12,53,54].
In the present study we examine the genetic and
cardiovascular risk characteristics of patients with neo-
vascular AMD in a multivariate segmentation analysis to
identify clusters of patients with distinct epidemiologic
and genetic risk profiles. To do this, we leverage a
clustering analytic approach, a multivariate method that
yields groups of individuals who have underlying similari-
ties across a number of different behavioral, attitudinal,
and/or demographic characteristics. In the public health
sector, standard clustering methods have been leveraged
to identify relevant subgroups of individuals with a parti-
cular disorder. For example, three distinct subgroups of
individuals with obsessive compulsive disorder have been
identified. Each group was characterized by pathophysio-
logic mechanisms and different treatment outcomes,
which may have significance in classifying and treating
these patients. Other clustering studies have been con-
ducted with suicidal psychiatric patients,[55] substance
abusers,[56] Parkinson’s Disease,[57] and caregivers of
eating disorder patients[58] among others.
Methods
Patients
The protocol was reviewed and approved by the Institu-
tional Review Boards at the Massachusetts Eye & Ear
Infirmary (MEEI), Boston, Massachusetts and conforms
to the tenets of the Declaration of Helsinki. Eligible
patients were enrolled in this study after they gave
informed consent either in person, over the phone, or
through the mail, before answering questions to a stan-
dardized questionnaire and donating 10 to 50 ml of
venous blood.
In this study of unrelated neovascular AMD, recruited
patients all had a sibling with normal maculae. This is
similar to what has been done in prior studies[55].
Details of the study design, and criteria for patient enroll-
ment, are described elsewhere[17,49,50,59]. In brief,
patients had the neovascular form of AMD in at least
one eye, defined by subretinal hemorrhage, fibrosis, or
fluorescein angiographic presence of neovascularization
documented at the time of, or prior to, enrollment in the
study. Disease status of every patient was confirmed by at
least two investigators by evaluation of fundus photo-
graphs and fluorescein angiograms (JWM and IKK).
Measures
Smoking
Patients were administered a standardized questionnaire
in person or via telephone to ascertain smoking
exposure, with the age of the patient at the time entry
into the study as the cutoff reference age for smoking
exposure. Data captured included the age when they
started smoking, the age when they quit smoking (if
they did quit), and the number of packs of cigarettes
smoked per day, on average. From these data the num-
ber of pack-years of cigarettes smoked was calculated
for each smoker. A pack-year was defined as one pack
of cigarettes per day for one year, with one pack defined
as twenty cigarettes. To reduce the impact of any
e x t r e m eo u t l y i n go b s e r v a t i o n s ,as i n g l ep a t i e n t ’sd a t a
were truncated to 140 pack-years.
Alcohol Consumption
Self reported alcohol consumption was measured as
grams of alcohol consumed per week, with 1 can, glass,
or bottle of beer considered equal to 12.8 g of ethanol,
one 4oz glass of wine equal to 11.0 g of ethanol, and
one drink or shot of liquor equal to 14.0 g of ethanol
[16,17]. Alcohol consumption was coded for these ana-
lyses as the sum of its presence versus absence for each
decade of life starting with the teen years until the dec-
ade of entry into the study. For example, a patient who
consumed alcohol for three decades received a value of
3.
Body Mass Index (BMI)
Self reported weight in pounds was recorded decade by
decade and then converted to kilograms, excluding years
of pregnancy from the 20’s until the decade of the
patient’s reference age. BMI was calculated as the cur-
rent weight divided by the square of the self-reported
height in meters at age 25 years. To reduce the impact
of any extreme outlying observations in analyses, two
patients’ data were truncated to a BMI of 40.
History of High Cholesterol and/or Hypertension
To classify patients has having a history of either condi-
tion, self-reported medication use was captured. Patients
were classified as having treated hypertension or
hypercholesterolemia if they had any period of at least
six months of regular use (at least twice per week) of an
anti-hypertensive, or statin or other cholesterol lowering
agent[17].
Genotypic Risk Characteristics
For the present analyses, two consistently associated
AMD-risk genetic markers (SNPs) were selected for
analysis. Their statistical association through family
based association testing and conditional logistic regres-
sion with neovascular AMD risk has been described in
detail previously[50,59]. We focused on variation in two
genes (CFH and ARMS2/HTRA1), known independently
to have the greatest influences on neovascular AMD
risk overall. Of the several significant single nucleotide
polymorphisms in each gene that have previously exam-
ined in this cohort,[49] we selected the inclusion of the
SNPs with the highest genotype frequency among the
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For CFH, the marker rs1061170 (Y402H) was selected,
with genotype frequencies in the study population of
CC 37.2%, CT 46.2%, and TT 16.6%. In prior research,
the CC genotype has been shown to be strongly asso-
ciated with neovascular AMD[50,60]. For ARMS2/
HTRA1, the marker rs1049331 was selected, with geno-
type frequencies in the study population of CC 30.8%,
TC 36.0%, and TT 33.2%. The TT genotype has also
been shown to be strongly associated with elevated risk
of neovascular AMD[60].
Segmentation Approach
The analytic approach used in the present study utilizes
techniques that are standard to the pharmaceutical
industry in the segmentation of physician and patient
populations. In brief, cluster analysis groups data objects
together based only on information describing their
characteristics or relationships. The goal is that the
objects within a group be similar (or related) to one
another and different from (or unrelated to) the objects
in other groups. Cluster analytic methods have a long
history of use in the life sciences. Some forty years ago
these methods were used to identify approximately simi-
lar subtypes in complex populations [61,62]. With the
advent of advanced computational methods, the array of
cluster analytic techniques has greatly expanded and
clustering techniques have been adopted in disciplines
as diverse as microarray image analysis;[63,64] the analy-
sis of human populations [65] and to market research
[66-69].
Traditional clustering methods fall into two broad
categories: relocation and hierarchical. Relocation clus-
tering methods – such as k-means and EM (expecta-
tion-maximization) – move records iteratively from one
cluster to another, starting from an initial partition until
an optimal set of clusters is identified. Hierarchical clus-
tering methods proceed in steps – producing a sequence
of partitions in which each one nests into the next parti-
tion in the sequence. Hierarchical clustering can be
either agglomerative or divisive. Agglomerative cluster-
ing starts with singleton clusters (clusters that contain
only one record) and proceeds by successively merging
the two “nearest neighbor” clusters at each stage. In
contrast, divisive clustering methods begin with one sin-
gle massive cluster that contains all records and then
proceeds by successively separating the cluster into
smaller ones.
In the present case, an industry standard two stage
analytic process was used to identify meaningfully dis-
tinct clusters of patients. First, a variant of Zhang’s
BIRCH (Balanced Iterative Reducing and Clustering
using Hierarchies) algorithm was used to create a preli-
minary group of clusters[70]. BIRCH is appropriate at
this initial stage given that the dataset contains both
nominal variables (e.g., sex) and ratio-scaled variables
(e.g., BMI). The final patient clusters were identified
from the BIRCH routine using a traditional agglomera-
tive routine[71]. In this second phase, smaller clusters
were merged into larger clusters, using change in the
Bayesian Information Criterion (BIC) as a criterion for
determining which clusters to join[72]. The standard
BIC was augmented by a careful review of several solu-
tions with larger and smaller numbers of clusters; none
of these alterative solutions provided the level of cluster
separation and ease of explanation. Similarly, solutions
with very small segment outputs were also rejected as
the final output should reflect meaningfully sized seg-
ments that could be reflected in the design of any future
drug development trials.
Results
To be included in these analyses, all patients had to
have complete data on all the variables under examina-
tion, resulting in a final N for analysis of 253 patients
(out of an initial evaluation of 352). The group of 253
neovascular AMD patients had a mean age of 73.1 (SD
= 7.4) years, and had a female majority (58.1%). The
overall mean of total smoking in pack-years for the
patient group was 26.7 (SD = 32.3). The overall patient
mean decades of alcohol use was 3.3 (SD = 2.2). The
overall patient mean for BMI was 26.5 (SD = 4.47).
Across all patients, 63.6% were classified as having a his-
tory of hypertension and 48.2% were considered to have
a history of hyperlipidemia.
The results of the segmentation modeling are
presented in Table 1. The 253 patients were classified
into four discrete and meaningfully different clusters
based on heterogeneity in the distributions of both phe-
notypic and genotypic characteristics. In this multivariate
model, the characteristics showing the greatest significant
heterogeneity across clusters were the history of hyper-
tension (F = 95.97, P < .001) and hypercholesterolemia
(F = 89.68, P < .001). More modest but still significant
differentiators were mean lifetime BMI (F = 4.58, P =
.004) and mean age (F = 3.74, P = .01). Other risk factors
did not significantly differentiate clusters among patients
with the disease: alcohol consumption (F = 1.10, P =
.351), gender (F = .605, P = .613), and smoking (F = .18,
P = .910).
In terms of the genetic markers, the distribution of
genotypes for both genes of interest did significantly dif-
ferentiate patients. The stronger differentiator was
clearly the marker rs1049331 in ARMS2/HTRA1,w i t h
marked differentiation most evident for the risk geno-
type TT (F = 101.28, P < .001), though the CC and TC
genotypes also significantly varied across clusters. The
CFH marker rs1061170 (Y402H) was less sensitive in
Feehan et al. BMC Medical Genetics 2011, 12:83
http://www.biomedcentral.com/1471-2350/12/83
Page 4 of 8discriminating between segments. The risk genotype for
this marker was only modestly differentiating (F = 5.06,
P = .002) relative to the non-risk genotypes.
The first segment of patients, Cluster 1 (28.1%), is
characterized as a group of patients where the clear
majority have a history of both treated high blood pres-
sure and hypercholesterolemia, who tend to be more
overweight but slightly younger than the other clusters.
Their genetic profile is mixed, with around half (52.1%)
carrying the ARMS2/HTRA1 TT risk genotype, and a
third (32.4) also carrying the CFH CC genotype (see
Table 1).
Similarly, Cluster 2 patients (33.2%) are highly likely to
have a history of treatment for hypertension (100%),
though just under half have co-morbid hypercholestero-
lemia treatment histories (45.2%). They tend to be the
oldest group of patients and are leaner than two of the
other clusters. In terms of the genetic factors, they do
not carry the ARMS2/HTRA1 rs1049331 TT risk geno-
type at all (0.0%), and less than half (41.7%) carry the
CFH Y402H CC risk genotype.
Cluster 3 patients (22.1%) have much better cardiovas-
cular profiles than those in Clusters 1 and 2, and when
they have accompanying pathology it is more likely to
be hypertension. Specifically, while just less than half
have a history of high blood pressure treatment (42.9%),
patients in cluster 3 are very unlikely to have been trea-
ted for hypercholesterolemia (1.8%). Patients in cluster 3
are highly likely to carry the ARMS2/HTRA1 rs1049331
TT risk genotype (83.9%), and a fifth carry the CFH
Y402H CC genotype (21.4%).
The final group, Cluster 4 (16.6%), have the healthiest
cardiovascular profile. They differ from Cluster 3 by
having a tendency toward hypercholesterolemia rather
than hypertension when there is accompanying pathol-
ogy. None of the neovascular patients in Cluster 4 have
a history of treated high blood pressure (0.0%), and only
around a quarter (28.6%) have a history of hypercholes-
terolemia (28.6%). No one in this group carries the
ARMS2/HTRA1 rs1049331 TT risk genotype (0.0%) but
they are the group most likely to carry the CFH Y402H
CC genotype (57.1%).
Discussion
In this analysis, various subtypes of patients with
neovascular AMD were identified and the resulting seg-
mentation was driven by both cardiovascular and genetic
risk profiles. However, not all factors shared equal weight
in creating the patient clusters. Importantly, several risk
factors associated with developing neovascular AMD or
its progression failed to differentiate clusters of patients
with the disease itself. Clearly, modifiable risk factors
such as alcohol consumption, body mass index, and
cigarette smoking should continue to be a focus of pre-
ventive intervention efforts. However, our analysis sug-
gests that once patients have end stage neovascular
AMD, patient variability in cardiovascular health, specifi-
cally hypertension and hypercholesterolemia, tends to
Table 1 Neovascular AMD Patient Clusters Defined by Phenotypic and Genotypic Risk Characteristics
Cluster % (N = 253) Cluster 1 Cluster 2 Cluster 3 Cluster 4 F Statisti P Value
n=7 1 n=8 4 n=5 6 n=4 2 c
28.1 33.2 22.1 16.6
Phenotypic Patient Characteristics
History of High Blood Pressure (%) 74.6 100.0 42.9 0.0 95.97 <.001
History of High Cholesterol (%) 100.0 45.2 1.8 28.6 89.68 <.001
BMI (± SD) 27.8 ± 4.7 26.4 ± 4.1 24.9 ± 4.5 26.8 ± 4.2 4.58 .004
Mean Age (± SD) 70.7 ± 8.4 74.5 ± 6.5 73.6 ± 6.9 73.9 ± 7.3 3.74 .012
Decades of Alcohol Consumption (± SD) 3.1 ± 2.2 3.2 ± 2.2 3.1 ± 2.2 3.8 ± 2.1 1.10 .351
Male Sex (%) 35.2 44.0 44.6 45.2 .605 .613
Mean Smoking in Total Pack Years (± SD) 25.4 ± 30.8 28.7 ± 31.4 25.3 ± 35.2 26.8 ± 33.4 .18 .910
Genotypic Patient Characteristics
HTRA1 rs1049331
TT* (%) 52.1 0.0 83.9 0.0 101.28 <.001
CC (%) 5.6 56.0 3.6 59.5 39.60 <.001
TC (%) 42.3 44.0 12.5 40.5 6.12 <.001
CFH rs1061170 (Y402H)
TT (%) 31.0 0.0 35.7 0.0 20.68 <.001
CC* (%) 32.4 41.7 21.4 57.1 5.06 .002
CT (%) 36.6 58.3 42.9 42.9 2.72 .045
*Risk alleles within each genotype
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kers of ARMS2/HTRA1). This has implications for the
design of clinical trials, which may increasingly focus on
the inclusion of genetic markers in their data collection
protocols.
This heterogeneity may provide insights to eventual
treatment development, or at the very least indicate sub-
populations who may be more (or less) responsive to
any potential agent targeting a vascular pathology and
any genetic networks/pathways that include ARMS2/
HTRA1 genotypes. Further, these results suggest that
any manufacturer developing pharmacological treat-
ments for the neovascular AMD population would need
to consider that the market potential for such an agent
may be limited. Any such therapy developed for a net-
work that includes ARMS2/HTRA1 m a yb eu n l i k e l yt o
affect Cluster 4, representing a reduction in market size
by almost a fifth of all neovascular AMD patients
(16.6%).
Similarly, if ARMS2/HTRA1 and/or the pathway it
functions in (currently the pathway it functions in is
unknown) became a focus of drug development, Cluster
2 patients represent a low-potential group that have
poor cardiovascular health, but do not carry the
ARMS2/HTRA1 homozygous risk TT genotype. How-
ever, Clusters 1 and 3 would represent a higher oppor-
tunity target sub-population of AMD patients, as they in
total represent 50.2% of the neovascular AMD popula-
tion, and tend to have high blood pressure in combina-
tion with a high likelihood of carrying the ARMS2/
HTRA1 TT genotype.
Currently, anti-VEGF therapies delivered via injection
(bevacizumab, pegaptanib, and ranibizumab) are the
best treatments for neovascular AMD. However, it has
been proposed that anti-VEGF therapies be contraindi-
cated in those patients with cardiovascular risk factors -
particularly high blood pressure (for review please see
Enseleit et al 2010)[73]. One could also foresee a sce-
nario where a potential new treatment that derives
( e v e ni np a r tf r o mARMS2/HTRA1) may be only suita-
ble for a smaller sample of the population. If, for exam-
ple, a new treatment carried some risk of elevated
cardiovascular events, then it may well be contraindi-
cated for Clusters 1 and 2, and the real market potential
may thus only be for Cluster 3.
Conclusions
In the future, it may important that efforts to identify
druggable targets for potential AMD treatments look
beyond bivariate tests of risk associations and take a
multi-factorial approach, taking into consideration the
fact that patients with the disease are very heteroge-
neous in their likelihood to have any genetic or cardio-
vascular profile of characteristics shown to elevate the
risk of disease. The patient clusters identified here
could reflect differential potential therapeutic targets
for pharmaceuticals. Consideration of their profiles
would allow drug developers to better design trials to
reflect the heterogeneity of the AMD population,
recognizing that subtypes of patients identified on the
basis of genetic and epidemiological factors may be dif-
ferentially responsive (or non-responsive or even
adversely responsive) to any potential therapeutic
agents in development.
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